back icon
close icon

Capture phrases in quotes for more specific queries (e.g. "rocket ship" or "Fred Lynn")

Article  June 1, 2015

Machine Learning Models and Pathway Genome Data Base for Trypanosoma cruzi Drug Discovery

SRI Authors Carolyn Talcott

Citation

COPY

Ekins, S., Lage de Siqueira-Neto, J., McCall, L. I., Sarker, M., Yadav, M., Ponder, E. L., . . . Talcott, C. (2015). Machine learning models and pathway genome data base for Trypanosoma cruzi drug discovery. PLOS Negelcted Tropical Diseases, 9(6), e0003878. doi: 10.1371/journal.pntd.0003878

Abstract

BACKGROUND:

Chagas disease is a neglected tropical disease (NTD) caused by the eukaryotic parasite Trypanosoma cruzi. The current clinical and preclinical pipeline for T. cruzi is extremely sparse and lacks drug target diversity.

METHODOLOGY/PRINCIPAL FINDINGS:

In the present study we developed a computational approach that utilized data from several public whole-cell, phenotypic high throughput screens that have been completed for T. cruzi by the Broad Institute, including a single screen of over 300,000 molecules in the search for chemical probes as part of the NIH Molecular Libraries program. We have also compiled and curated relevant biological and chemical compound screening data including (i) compounds and biological activity data from the literature, (ii) high throughput screening datasets, and (iii) predicted metabolites of T. cruzi metabolic pathways. This information was used to help us identify compounds and their potential targets. We have constructed a Pathway Genome Data Base for T. cruzi. In addition, we have developed Bayesian machine learning models that were used to virtually screen libraries of compounds. Ninety-seven compounds were selected for in vitro testing, and 11 of these were found to have EC50 < 10μM. We progressed five compounds to an in vivo mouse efficacy model of Chagas disease and validated that the machine learning model could identify in vitro active compounds not in the training set, as well as known positive controls. The antimalarial pyronaridine possessed 85.2% efficacy in the acute Chagas mouse model. We have also proposed potential targets (for future verification) for this compound based on structural similarity to known compounds with targets in T. cruzi.

CONCLUSIONS/ SIGNIFICANCE:

We have demonstrated how combining chemoinformatics and bioinformatics for T. cruzi drug discovery can bring interesting in vivo active molecules to light that may have been overlooked. The approach we have taken is broadly applicable to other NTDs.

How can we help?

Once you hit send…

We’ll match your inquiry to the person who can best help you. Expect a response within 48 hours.

Our Privacy Policy